Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight"
Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most su...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_71e01208e20a4ebd8aa898559bef0639 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Romain Eychenne |e author |
| 700 | 1 | 0 | |a Michel Chérel |e author |
| 700 | 1 | 0 | |a Férid Haddad |e author |
| 700 | 1 | 0 | |a François Guérard |e author |
| 700 | 1 | 0 | |a Jean-François Gestin |e author |
| 245 | 0 | 0 | |a Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight" |
| 260 | |b MDPI AG, |c 2021-06-01T00:00:00Z. | ||
| 500 | |a 10.3390/pharmaceutics13060906 | ||
| 500 | |a 1999-4923 | ||
| 520 | |a Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed. | ||
| 546 | |a EN | ||
| 690 | |a targeted alpha therapy | ||
| 690 | |a α-emitters | ||
| 690 | |a actinium-225 | ||
| 690 | |a astatine-211 | ||
| 690 | |a bismuth-212 | ||
| 690 | |a bismuth-213 | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceutics, Vol 13, Iss 6, p 906 (2021) | |
| 787 | 0 | |n https://www.mdpi.com/1999-4923/13/6/906 | |
| 787 | 0 | |n https://doaj.org/toc/1999-4923 | |
| 856 | 4 | 1 | |u https://doaj.org/article/71e01208e20a4ebd8aa898559bef0639 |z Connect to this object online. |